MRG007-001/ARR-217-101: An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants with Unresectable Locally Advanced or Metastatic Solid Tumors
This is an open-label, multi-center, phase I/II study to evaluate the safety, efficacy, and pharmacokinetics of MRG007 in patients with unresectable locally advanced and metastatic solid tumors.
Why this Research Matters
This is an open-label, multi-center, phase I/II study to evaluate the safety, efficacy, and pharmacokinetics of MRG007 in patients with unresectable locally advanced and metastatic solid tumors.
Who can Participate
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study. https://clinicaltrials.gov/study/NCT07066657?term=NCT07066657&rank=1
Study ID
Protocol Number: 25-2495
More information available at ClinicalTrials.gov: NCT07066657
Meet the Team
Principal Investigator